Makro-Albumon (Human Albumin As Macroaggregates)

The macroaggregated albumin particles are calibrated to a specific size range that allows them to become temporarily trapped in the small vessels of the lungs after intravenous injection. When labeled with a radiotracer, these particles emit gamma radiation that can be detected by a gamma camera, producing a detailed map of pulmonary perfusion.

The dose of Makro-Albumon is determined by the prescribing physician based on the specific imaging protocol, patient weight, and clinical indication. Healthcare professionals calculate the appropriate activity of the radiolabeled preparation and the volume of macroaggregated albumin to administer for each individual case.

Safety data for Makro-Albumon in pregnant or breastfeeding individuals are limited. Because the product involves a radiopharmaceutical component, it is generally avoided unless the diagnostic benefit outweighs potential risks. Clinicians should discuss any concerns with the patient and consider alternative imaging methods when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Makro-Albumon uses human albumin macroaggregates as the carrier for the radiotracer, offering a well‑characterized particle size distribution that provides reliable capillary lodging. Compared with alternative agents such as technetium‑99m labeled macroaggregated albumin from other manufacturers, Makro-Albumon meets EU quality standards and is supplied with consistent sterility and particle uniformity, which can improve imaging reproducibility.

Makro-Albumon must be stored refrigerated at 2‑8 °C. The vials should be kept in their original packaging, protected from light, and must not be frozen or shaken. Prior to administration, allow the product to reach room temperature if required by the imaging protocol, and inspect for any particulate matter or discoloration.

Makro-Albumon is administered intravenously by a qualified healthcare professional. The prepared radiolabeled suspension is injected slowly, typically through a peripheral vein, while the patient is monitored for vital signs. The injection is followed by imaging with a gamma camera to capture the distribution of the radiotracer within the lungs.

The most serious risks include severe allergic reactions such as anaphylaxis, marked hypotension, and rare embolic events that can compromise pulmonary circulation. Patients should be observed closely during and after injection, and emergency measures must be readily available to manage any acute adverse reactions.

Makro-Albumon is contraindicated in individuals with known hypersensitivity to human albumin or any component of the formulation, patients with severe pulmonary hypertension, uncontrolled heart failure, or those who have experienced a severe reaction to a previous macroaggregated albumin scan. Clinicians should evaluate each patient’s medical history before administration.